Overview

A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis

Status:
Completed
Trial end date:
2002-08-01
Target enrollment:
Participant gender:
Summary
To investigate the ability of Sativex to relieve central neuropathic pain in multiple sclerosis subjects.
Phase:
Phase 3
Details
Lead Sponsor:
GW Pharmaceuticals Ltd.
Treatments:
Nabiximols